Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
Date:11/7/2008

omers, competition, government regulation and approvals, and general economic conditions. For example, if our clinical trials are not successful or take longer to complete than we expect, we may not be able to develop and commercialize our products. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission. Such filings are available on our website or at http://www.sec.gov. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstance.

Financial Information

SCOLR Pharma, Inc.

BALANCE SHEET

September 30, December 31,

2008 2007

(Unaudited)

ASSETS

Current Assets

Cash and cash equivalents $8,908,986 $11,825,371

Accounts receivable 244,214 225,900

Interest and other receivables - 16

Prepaid expenses and other assets 323,407 432,213

Total current assets 9,476,607 12,474,500

Property and Equipment - net of

accumulated depreciation of

$1,213,775 and $964,738, respectively 502,510 748,931

Intangible assets - net of

accumulated amortization of $443,435

and $385,452, respectively 522,403 464
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
3. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
4. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 /PRNewswire/ ... company") announced today that the company,s board of directors approved ... to June 30. Accordingly, DelMar will file a Transition Form ... Jeffrey Bacha , president and CEO of DelMar stated, "The ... achieving our goal of obtaining a senior exchange listing for ...
(Date:7/24/2014)... Sciences, Inc. (NASDAQ: ALIM ) ("Alimera"), a ... commercialization of prescription ophthalmic pharmaceuticals, today announced that it ... financial results after the market close on Thursday, August ... the same day at 4:30 p.m. ET. ... Dan Myers , President and Chief Executive Officer, and ...
(Date:7/24/2014)... , July 24, 2014  Perrigo Company (NYSE: ... received an AB therapeutic equivalent rating from the U.S. ... New Drug Application (NDA) for testosterone gel 1.0%. FDA ... [AbbVie,s] AndroGel 1% and can be substituted with the ... effect and safety profile as AndroGel 1% when used ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3Alimera Sciences To Release Second Quarter 2014 Results 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3
... N.J. , July 12 Timothy G. Hayes , currently ... North America , will also lead the business unit,s Global Business Development ... , , ... the United States , Canada and Puerto Rico , ...
... July 13 A new free, white paper that guides ... Food and Drug Administration (FDA) regulations to combination products embedded with ... http://www.microtestlabs.com/combination-products-20/ ) , , ... Combination products are a large and growing segment of the medical ...
Cached Medicine Technology:Timothy G. Hayes Appointed Head of Global Business Development for Bayer HealthCare Consumer Care 2Timothy G. Hayes Appointed Head of Global Business Development for Bayer HealthCare Consumer Care 3New White Paper Helps Medical Device Manufacturers Apply New FDA Regs to Combination Products 2New White Paper Helps Medical Device Manufacturers Apply New FDA Regs to Combination Products 3New White Paper Helps Medical Device Manufacturers Apply New FDA Regs to Combination Products 4
(Date:7/25/2014)... 25, 2014 A report released by the ... fiscal year 2013 (July 1, 2012- June 30, 2013). , ... the JDRF is the largest single funder of type 1 ... and relationships with most of the top research centers. ... for type 1 diabetes in the near future. , Since ...
(Date:7/25/2014)... Steven Reinberg HealthDay Reporter ... low" number of girls and boys are getting the human ... cancers, U.S. health officials said Thursday. The U.S. Centers ... aged 11 and 12 get the three-dose vaccine so that ... Yet, despite a slight increase over the ...
(Date:7/25/2014)... reactions and desires in initial romantic encounters determine the ... of those initial "sparks" necessary to fuel sexual desire ... be a desirable trait for both men and women ... in the other person? Do men perceive responsive women ... for women,s perceptions of men? A study published in ...
(Date:7/25/2014)... Home Care Assistance – Halton/Peel Region ... in-home senior care, is weighing in on the recent ... projects in Alberta through their New Horizons for Seniors ... is a federal grants and contributions program that supports ... difference in the lives of others and in their ...
(Date:7/25/2014)... ZeptoMetrix™ Corporation (ZMC), an industry leader ... and services for infectious disease diagnostic development, is ... Multimarker Controls - MDZ001 . , An ... marked, unassayed external run control intended for use ... Multimarker Controls - MDZ001 has been specifically designed ...
Breaking Medicine News(10 mins):Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2Health News:Too Few Teens Receive HPV Shot, CDC Says 2Health News:Too Few Teens Receive HPV Shot, CDC Says 3Health News:Why do men prefer nice women? 2Health News:Why do men prefer nice women? 3Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 2Health News:Home Care Assistance – Halton/Peel Region Weighs in on Alberta Communities Receiving Funding to Support Seniors and Senior Caregivers 3Health News:ZeptoMetrix™ Corporation (ZMC) Releases FDA Class 1 Exempt, IVD and CE Labeled NATtrol™ RP Multimarker Controls 2
... avoid exposure to the fumes of solvents used in ... lacquers//, could give rise to allergies in young children, ... environmental agency. ,Pregnant women should leave renovation ... clear of the work area altogether. ,'It ...
... also suffer from diseases that could be aggravated by alcohol ... drinking alcohol, face the risk of higher death rates, when ... have any such complications. ,Older men who drank moderately ... by alcohol use such as gout or ulcer disease, or ...
... has warned the nation's betel-nut chewers of the increased ... habits like smoking and drinking. ,According to ... National Health Research Institute when betel nut chewing was ... cancer of the esophagus was about 195 times higher ...
... most companies have stopped supply citing 'anomalies' in the Value ... have withdrawn the supply of drugs due to confusion over ... shortage has put patients in a difficult situation as medicines ... stock. The patients are getting medicines from neighbouring states. ...
... Philippines is witness to a yearly exodus phenomenon of ... their land for raking// in the moolah elsewhere! This ... against serious implications on the country’s health services. According ... grave with nearly 85% of the nursing population, settled ...
... the Federal Government has put together a coherent and long-term ... as well as ease the burden on their carers. He ... mental health, including new Medicare rebates for consultations with psychologists ... could be a big difference, with a concerted contribution from ...
Cached Medicine News:Health News:Alcoholism Linked To Higher Death Rates Among Older Men 2Health News:Cancer Risks for Betel Nut Chewers 2Health News:Medicare Benefits For Patients seeking Psychiatric Help 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: